ALLR
ALLR
NASDAQ · Biotechnology

Allarity Therapeutics Inc

$1.09
+0.05 (+4.81%)
Financial Highlights (FY 2026)
Revenue
6.37B
Net Income
-1,905,604,623
Gross Margin
Profit Margin
-11,927.5%
Rev Growth
D/E Ratio
0.11
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 55.4% 55.4% 55.4%
Operating Margin -14,675.8% -22.3% -24.2% -22.7%
Profit Margin -11,927.5% -29.6% -25.2% -30.8%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 6.37B 2.19M 1.96M 2.40M
Gross Profit 1.21M 1.09M 1.33M
Operating Income -935,266,186,134 -487,059 -473,882 -545,220
Net Income -1,905,604,623 -647,190 -493,473 -738,397
Gross Margin 55.4% 55.4% 55.4%
Operating Margin -14,675.8% -22.3% -24.2% -22.7%
Profit Margin -11,927.5% -29.6% -25.2% -30.8%
Rev Growth +18.0% +10.8% +10.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 882.5K 1.72M 1.54M 1.78M
Total Equity 7.72M 6.23M 6.69M 6.01M
D/E Ratio 0.11 0.28 0.23 0.30
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -2,736,795,749 -712,204 -583,546 -705,797
Free Cash Flow -781,686 -525,232 -735,953